Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values
✍ Scribed by Cui Liyan; Zhang Jie; Hu Xiaozhou
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 93 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Recent studies have suggested that heart‐type fatty acid‐binding protein (H‐FABP) may detect ongoing myocardial damage involved in the progression of acute coronary syndromes (ACS). This study was prospectively designed to examine whether the combination of H‐FABP, a marker for ongoing myocardial damage, and ischemia‐modified albumin (IMA), a marker for myocardial ischemia, would effectively diagnose patients with ACS. H‐FABP values above 1.5 µg/l can be correctly measured via an ELISA and 6 µg/l is the currently used cut‐off value (1–3). We measured serum H‐FABP and IMA of 108 patients on admission within 12 hr after onset of chestpain and normal troponin T. serum samplesfrom ACS group (n=82) had decreased capacity of ACB [64 (61–67) U/ml] compared with non‐ACS ischemic chest pain group (n=26) samples [75 (71–78) U/ml] (P<0.05). The combination of IMA and H‐FABP usually had better sensitivity [96.3% (92.2–100%)] (P<0.05) and accuracy [92.6 (87.7–97.5%)] (P<0.05) than when individually used. Thus, the combination of H‐FABP and IMA measurements after initiation of chest pain may be highly effective for risk stratification in patients with ACS and normal cardiac troponin T. J. Clin. Lab. Anal. 23:14–18, 2009. © 2009 Wiley‐Liss, Inc.